Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study
Author:
Abenavoli Ludovico1ORCID, Spagnuolo Rocco1ORCID, Scarlata Giuseppe Guido Maria1ORCID, Scarpellini Emidio2ORCID, Boccuto Luigi3ORCID, Luzza Francesco1ORCID
Affiliation:
1. Department of Health Sciences, University “Magna Graecia”, Viale Europa, 88100 Catanzaro, Italy 2. Translationeel Onderzoek van Gastroenterologische Aandoeningen (T.A.R.G.I.D.), Gasthuisberg University Hospital, KU Leuven, Herestraat 49, 3000 Leuven, Belgium 3. Healthcare Genetics and Genomics Doctoral Program, School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, Clemson, SC 29631, USA
Abstract
Background and Objectives: Inflammatory bowel disease (IBD) is a condition characterized by chronic intestinal inflammation. We can identify two major forms: Crohn’s disease (CD) and ulcerative colitis (UC). One of the extraintestinal manifestations of IBD is nonalcoholic fatty liver disease (NAFLD). IBD and NAFLD share common pathogenetic mechanisms. Ultrasound (US) examination is the most commonly used imaging method for the diagnosis of NAFLD. This cross-sectional observational retrospective study aimed to evaluate the US prevalence of NAFLD in IBD patients and their clinical features. Materials and Methods: A total of 143 patients with IBD underwent hepatic US and were divided into two different groups according to the presence or absence of NAFLD. Subsequently, new exclusion criteria for dysmetabolic comorbidities (defined as plus) were applied. Results: The US prevalence of NAFLD was 23% (21% in CD and 24% in UC, respectively). Most IBD–NAFLD patients were male and older and showed significantly higher values for body mass index, waist circumference, disease duration, and age at onset than those without NAFLD. IBD–NAFLD patients showed a significantly higher percentage of stenosing phenotype and left-side colitis. Regarding metabolic features, IBD–NAFLD patients showed a significantly higher percentage of hypertension and IBD plus dysmetabolic criteria. Also, higher values of alanine aminotransferase and triglycerides and lower levels of high-density lipoproteins are reported in these patients. Conclusions: We suggest performing liver US screening in subjects affected by IBD to detect NAFLD earlier. Also, patients with NAFLD present several metabolic comorbidities that would fall within the new definition of metabolic-associated fatty liver disease. Finally, we encourage larger longitudinal studies, including healthy controls, to provide further confirmation of our preliminary data.
Reference46 articles.
1. Spagnuolo, R., Larussa, T., Iannelli, C., Cosco, C., Nisticò, E., Manduci, E., Bruno, A., Boccuto, L., Abenavoli, L., and Luzza, F. (2020). COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. Medicina, 56. 2. Malik, T.F., and Aurelio, D.M. (2023). StatPearls, StatPearls Publishing. 3. Extra-intestinal manifestations of inflammatory bowel diseases;Marotto;Pharmacol. Res.,2020 4. Martínez-Domínguez, S.J., García-Mateo, S., Laredo, V., Gargallo-Puyuelo, C.J., Gallego Llera, B., López de la Cruz, J., and Gomollón, F. (2023). Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers, 15. 5. Abenavoli, L., Giubilei, L., Procopio, A.C., Spagnuolo, R., Luzza, F., Boccuto, L., and Scarpellini, E. (2022). Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay. Nutrients, 14.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|